Idera Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, September 2011, Pages: 69

Idera Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Idera Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011” provides data on the Idera Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Idera Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Idera Pharmaceuticals, Inc. and industry–specific third party sources, put together by Global Markets Direct’s team.

Scope

- Idera Pharmaceuticals, Inc. - Brief Idera Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Idera Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Idera Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Idera Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Idera Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Idera Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Idera Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Idera Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Idera Pharmaceuticals, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Idera Pharmaceuticals, Inc. Snapshot
Idera Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Idera Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Idera Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Idera Pharmaceuticals, Inc. – Pipeline Products Glance
Idera Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Idera Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Idera Pharmaceuticals, Inc. – Drug Profiles
IMO-2134
Product Description
Mechanism of Action
R&D Progress
IMO-4200 + Rituximab
Product Description
Mechanism of Action
R&D Progress
Idera Pharmaceuticals, Inc. – Pipeline Analysis
Idera Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Idera Pharmaceuticals, Inc. - Pipeline Products By Target
Idera Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Idera Pharmaceuticals, Inc. – Recent Pipeline Updates
Idera Pharmaceuticals, Inc. – Company Statement
Idera Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
May 31, 2005: Idera Announces The Initiation of QAX935 By Novartis.
Oct 30, 2010: Idera Presents Phase I Data On IMO-2125 Demonstrating Induction Of Broad Antiviral Immune Response In Null-Responder HCV Patients At AASLD Meeting 2010
Oct 29, 2010: Idera Announces Data Presentation Of Toll-Like Receptor 3 Agonist Compounds At Immunological Mechanisms Of Vaccination Keystone Meeting
Jan 28, 2010: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial Of IMO-3100
Aug 27, 2010: Idera Achieves Clinical Milestone Under Collaboration With Merck KGaA For Cancer Treatment
Feb 24, 2010: Idera Presents Mechanism Of Action Data On IMO-3100
Jun 23, 2011: Idera Pharmaceuticals Presents Mechanism Of Action Data Of IMO-3100 In Preclinical Model Of Arthritis At FOCIS 2011 Annual Meeting
Apr 22, 2011: Idera Pharmaceuticals Delays Initiation Of Phase II Clinical Trial Of IMO-2125 In Treatment-Naïve HCV Patients
Dec 21, 2009: Idera Pharmaceuticals Announces Positive Interim Phase 1 Clinical Trial Results Of IMO-2125 For The Treatment Of Chronic Hepatitis C
Oct 21, 2010: Idera Announces Phase I Clinical Results Of IMO-3100 For Treatment Of Autoimmune Diseases
Dec 20, 2010: Idera Reports Preliminary Data From Phase I HCV Trial Of IMO-2125 In Combination With Ribavirin
Jul 20, 2011: Idera Reports Clinical Hold On Proposed Phase II Clinical Trial Of IMO-3100
Dec 19, 2007: Merck And Idera Pharmaceuticals To Collaborate On Development Of Tlr9 Agonists For Treatment Of Cancer.
Jan 19, 2010: Idera Pharmaceuticals Achieves Clinical Milestone For Initiation Of Phase 2 Trial Of EMD 1201081
Mar 18, 2010: Idera Announces Acceptance Of IMO-2125 Abstracts For Presentation At EASL Annual Meeting
Nov 17, 2010: Idera Presents Preclinical Data On Mechanism Of Action Of TLR Antagonist Candidate In Model Of Hyperlipidemia At AHA Meeting
Sep 17, 2007: Idera Pharmaceuticals Initiates Phase I Trial of IMO-2125 in Hepatitis C
Sep 17, 2007: Idera Pharmaceuticals Presents Preclinical Data on IMO-2125 At The 47th Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) In Chicago
Apr 15, 2010: Idera Announces Positive Phase I Data Of IMO-2125 In Null Responder HCV Patients At EASL 2010
Feb 14, 2011: Idera Pharmaceuticals Presents Data On IMO-3100 In Preclinical Lupus Model Showing Suppression of Disease Progression Parameters
Feb 14, 2010: Idera Pharmaceuticals Presents Preclinical Hyperlipidemia Data On A TLR7/9 Antagonist At Keystone Symposium
Oct 11, 2009: Idera Pharmaceuticals Presents Preclinical Data at ACR/ARHP 2009 Annual Meeting on IMO-3100, a Toll-Like Receptor Antagonist, in Combination with Enbrel(R) in Arthritis Model
Nov 09, 2010: Idera Presents Preclinical Data From Autoimmune Disease Program At ACR 74th Annual Scientific Meeting
Jun 08, 2010: Idera Announces Preliminary Data From Phase I Clinical Trial Of IMO-3100 For Treatment Of Autoimmune And Inflammatory Diseases
Mar 08, 2011: Idera Pharmaceuticals Announces IMO-2125 Data Presentation At Annual Meeting Of European Association For Study Of Liver
Oct 07, 2009: Idera Pharmaceuticals Initiates Phase 1 Clinical Trial Of IMO-2125, A TLR9 Agonist, In Combination With Ribavirin For Chronic Hepatitis C Virus Infection
Dec 06, 2010: Idera Presents Preclinical Data On Dual Agonist Of TLR7 and TLR8, IMO-4200, At American Society For Hematology Meeting
Dec 06, 2010: Idera Presents Preclinical Data on Dual Agonist of TLR7 and TLR8, IMO-4200, at American Society for Hematology Meeting
Dec 06, 2010: Idera Presents Preclinical Data On IMO-4200 In Combination With Bortezomib At ASH Annual Meeting
Apr 04, 2011: Idera Presents Data From Multiple-Dose Phase I Clinical Trial Of IMO-3100
Nov 03, 2009: Idera Pharmaceuticals Presents Preclinical Data On IMO-2125, Its Lead Drug Candidate For Chronic Hepatitis C Virus Infection, At Liver Meeting 2009
Apr 02, 2011: Idera Presents Data From Phase I Clinical Trial Of IMO-2125 In Treatment-Naive Genotype 1 HCV Patients At EASL 2011
Oct 01, 2010: Idera Presents IMO-2125 Data For Treatment Of HCV Infection At AASLD Annual Meeting
May 01, 2005: Idera Announces That Novartis Initiated A Phase 1 Clinical Study Of QAX935, A Novel TLR9 Agonist Identified Under The research collaboration.
Financial Deals Landscape
Idera Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2011
Idera Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2011
Idera Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
Idera Pharmaceuticals, Inc. Detailed Deal Summary
Equity Offering
Idera Pharmaceuticals Completes Private Placement Of $10 Million
Idera Pharmaceuticals Completes Private Placement Of $4 Million
Idera Pharmaceuticals Completes Private Placement Of $3.5 Million
Idera Pharmaceuticals Completes Private Placement Of $9.75 Million
Debt Offering
Idera Pharmaceuticals Completes Private Placements Of Convertible Notes For $5 Million
Idera Pharmaceuticals Extends Research Collaboration Agreement With Merck
Idera Pharmaceuticals Extends Its Agreement With Merck
Idera Pharmaceuticals Extends Its Agreement With Novartis
Idera Pharmaceuticals Terminates Research Collaboration Agreement With Novartis
Licensing Agreements
Idera Pharmaceutical Enters Into Licensing Agreement With Merck
Merck Signs An Agreement With Idera Pharmaceuticals
Idera Pharmaceuticals Enters Into Licensing Agreement With Merck
Alnylam Enters Into License Agreement With Hybridon
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Idera Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Idera Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Idera Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Idera Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Idera Pharmaceuticals, Inc. - Phase I, H2 2011
Idera Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Idera Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Idera Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
Idera Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Idera Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
Idera Pharmaceuticals, Inc., Deals Summary by Region, 2004 to YTD 2011
Idera Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011

List of Figures
Idera Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Idera Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Idera Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Idera Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Idera Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011
Idera Pharmaceuticals, Inc. - Pipeline By Target, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• Analysis of Google Inc